Abstract: Objective: To evaluate the efficacy and safety of three-times the dose of Ebastine in the treatment of the patients with atopic dermatitis (AD). Methods: The patients with mild to moderate AD were collected and were divided into the observation group and the control group randomly. The patients in the observation group were treated with Ebastine 30mg/d，orally and topical Vaseline and those in the control group was treated with Ebastine 10mg/d, orally and topical Vaseline. After 28 days of the treatment, the itching score, SCORAD score, total clinical efficacy rate and adverse reaction were assessed. Results: A total of 128 patients were collected (64 patients in each group). The itching score and SCORAD in the observation group were 3.02±1.19 and 21.83±3.05, which were lower than those in the control group (6.77±1.33 and 29.28±4.91), with significant differences (P<0.05). The efficacy in the observation group was 93.33%, which was higher than that in the control group (68.75%), with a significant difference (P<0.05). The adverse reaction rate in the observation group and control group were 6.3% and 9.4% respectively, with no significant difference (P>0.05). Conclusion: 30mg/d Ebastine in the treatment of atopic dermatitis is more effective than 10mg/d, with similar adverse reaction.

Key words: atopic dermatitis, ebastine, efficacy, safety